Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 118   

Articles published

JNJ 99.60 +0.40 (0.40%)
price chart
3 Drugs Critical to Johnson & Johnson's Future
Johnson & Johnson (NYSE: JNJ ) is one of the planet's largest companies with operations that stretch from consumer goods to medical devices, but it's drug business growth has led to J&J's climbing sales.
Market Reaction To Johnson & Johnson's Earnings Is Justified
Johnson & Johnson's stock price fell sightly following its Q3 2014 earnings announcement despite the company beating consensus estimates and keeping the full year outlook the same.
Johnson & Johnson to Buy Biotech Company Alios BioPharma
The deal has been approved by the boards of both companies, and is the first acquisition in some time for Johnson & Johnson, which has been more focused on selling assets than buying them this year. In March, Johnson & Johnson sold its K-Y brand of ...
Johnson & Johnson Buying Alios for $1.75B  ABC News
What Johnson & Johnson's Alios Acquisition Means for Gilead Sciences  Barron's (blog)
Related articles »  
What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock
Johnson & Johnson (NYSE: JNJ ) is one of the planet's biggest drugmakers. Its drugs are used for a variety of diseases, including cancer and autoimmune disorders, but it's J&J's sales of the hepatitis C drug Olysio that are most interesting to Gilead ...
Related articles »  
Yale program now processing requests for Johnson & Johnson pharmaceutical ...
The Yale University Open Data Access (YODA) Project is now receiving and processing requests for pharmaceutical clinical trial research data provided by Janssen, the Pharmaceutical Companies of Johnson & Johnson. Requests can be directly submitted to ...
J&J sales top forecast, helped by drug for hep C
At the end of September, Johnson & Johnson announced plans to buy Alios BioPharma, a biotech company focused on developing existing therapies for viral diseases.
Why I'm in Johnson & Johnson for the long run  The Globe and Mail
Johnson & Johnson raises forecast for a third time  Salt Lake Tribune
Related articles »  
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson JNJ -0.24% (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »  
Why Johnson & Johnson (JNJ) Stock Is Up Today
NEW YORK (TheStreet) -- Johnson & Johnson (JNJ) shares are higher by 0.45% to $97.44 after the company reported third quarter net income of $4.7 billion, or $1.66 per diluted share, compared to $2.9 billion, or $1.04 per diluted share, for the same ...
Johnson & Johnson Earnings: Pharmaceutical Sales Again Lead the Way  Motley Fool
J&J's revenue up, but near flat sales growth in medical devices ...  Philly.com (blog)
Related articles »  
Johnson & Johnson Earnings Preview: Pharma Is Where The Party Is
This year has been eventful for Johnson & Johnson. The company completed the divestiture of Ortho-Clinical Diagnostics to Carlyle Group in Q3 2014 and got the approval for its new blockbuster drug Olysio in Europe in the second quarter.
Related articles »  
Update: Johnson & Johnson Posted Impressive Q3 Earnings - Buy The Stock (JNJ)
Johnson & Johnson posted strong financial results in the third quarter of 2014, with revenue and EBITDA rising. The stock corrected ~10% from the top in the last three months, as I expected.